BARDA INDUSTRY DAY

Core Service Support for MCM Advanced Development & Manufacturing

R. Thomas Warf, Director
Division of Manufacturing, Facilities & Engineering
HHS/OS/ASPR/BARDA

Monday, December 10, 2012
MFE Mission

Provide advanced development, manufacturing capabilities and production surge capacity as core services for medical countermeasure (MCM) programs to address national security and to augment public health needs on a cost-effective, reliable, and sustainable basis.
SUBJECT MATTER EXPERTISE

• Large & Small Molecule Manufacturing
• Process Development
• Logistics & Readiness
• Cold Chain
OVERSEE BARDA’s CAPACITY BUILDING INVESTMENTS:

MedImmune / Philadelphia, PA
Double LAIV Filling Capacity

Novartis Vaccines Division / Holly Springs, NC
U.S.-Based Flu Cell Culture Facility (USFCC)

sanofi pasteur / Swiftwater, PA
Retrofit of Egg-based
CIADM = Centers for Innovation in Advanced Development and Manufacturing

3 Awards on June 15, 2012
Establish public-private partnerships to construct/retrofit U.S.-based, commercial-scale, biopharmaceutical facilities that support advanced development and manufacturing of Medical Countermeasures (MCMs) to provide...

...core services, on a routine basis, for the advanced development and manufacturing of biopharmaceutical MCMs supported by the U.S. Government;

...in an emergency, necessary U.S.-based surge capacity to respond to an emerging infectious disease, pandemic influenza, and currently known or unknown threats;

...biopharmaceutical oriented workforce development through training programs aligned with current regulatory guidelines.
FFMN = *Fill Finish Manufacturing Network*

Solicitation 12-100-SOL-00010

*Proposals Due - September 27, 2012*

**Task I:** Augment Current U.S.-based Fill & Finish Manufacturing Capacity

**Task II:** Provide Fill & Finish Manufacturing ‘Core Services’

**Task III:** Provide Biopharmaceutical Production Surge Capacity